Aura Biosciences Inc ((AURA)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Aura Biosciences Inc (AURA) is conducting a Phase 3 clinical trial titled ‘A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma.’ This study aims to assess the safety and efficacy of belzupacap sarotalocan (bel-sar) in treating patients with primary indeterminate lesions or small choroidal melanoma, conditions that can lead to severe ocular complications.
The intervention being tested involves the administration of bel-sar, a drug delivered via a suprachoroidal microinjector followed by an infrared laser application. This treatment is compared against a sham control involving a sham injection and laser.
The study is designed as a randomized, double-masked, controlled trial with a parallel intervention model. Participants, outcomes assessors, and sponsors are masked to ensure unbiased results. The primary purpose of the study is treatment-focused.
The trial began on August 17, 2023, and is currently recruiting participants. The last update was submitted on September 9, 2025, indicating ongoing progress. The primary completion and estimated study completion dates have not been disclosed yet.
This update could potentially influence Aura Biosciences’ stock performance positively, as successful trial results may enhance the company’s market position in ocular oncology. Investors should monitor this study’s progress, considering the competitive landscape in the treatment of ocular melanoma.
The study is ongoing, with further details available on the ClinicalTrials portal.